| Literature DB >> 31929778 |
Khaled R Alkharsah1, Alhussain J Alzahrani2, Obeid E Obeid1, Reem Y Aljindan1, Adnane Guella3, Amein K Al-Ali1, Hussain R Al-Turaifi4, Talal A Sallam5.
Abstract
BACKGROUND: Hepatitis C virus (HCV) is a major health problem, particularly in high-risk groups such as kidney transplant recipients, where it can adversely affect graft survival and increase the relative risk for mortality. Recently, the role of genetic variation among HCV patients in determining the outcome of infections has been under investigation.Entities:
Keywords: Hepatitis C virus; Saudi Arabia; interleukin-28B; interleukin-6; kidney transplant
Year: 2019 PMID: 31929778 PMCID: PMC6945315 DOI: 10.4103/sjmms.sjmms_175_18
Source DB: PubMed Journal: Saudi J Med Med Sci ISSN: 2321-4856
Data of the hepatitis C virus-positive kidney transplant recipients
| Sex | Age years | Blood group | Period since transplantation date (years) | Transplantation place | Donor | Cause of renal failure | HCV viral load copies/ml |
|---|---|---|---|---|---|---|---|
| Male | 47 | O+ | 1.6 | KSA | Live | Glomerulonephritis | 13,513 |
| Female | 23 | O+ | 6.6 | Iran | Live | SLE | 13,601 |
| Female | 54 | B+ | 1.8 | KSA | Live | Glomerulonephritis | 13,945 |
| Female | 34 | B+ | 3.9 | KSA | Live | Unknown | 14,021 |
| Female | 55 | O+ | 4.3 | Egypt | Live | Diabetic nephropathy | 14,233 |
| Male | 69 | O− | 7.7 | The Philippines | Live | Unknown | 15,123 |
| Female | 48 | O+ | 2.3 | Pakistan | Live | Glomerulonephritis | 15,700 |
| Female | 32 | O+ | 8.7 | The Philippines | Live | Renal stone | 15,700 |
| Male | 43 | A+ | 15 | KSA | Live | Hypertension | 18,910 |
| Male | 30 | O+ | 4.7 | KSA | Cadaver | Alport syndrome | 45,990 |
| Male | 43 | O+ | 6.9 | Pakistan | Live | Unknown | 78,553 |
| Female | 42 | O+ | 7.2 | Egypt | Live | Glomerulonephritis | 78,910 |
| Male | 35 | O+ | 3.8 | Pakistan | Live | Hypertension | 79,000 |
| Female | 36 | AB+ | 11 | KSA | Live | Unknown | 297,128 |
| Female | 53 | AB+ | 5.7 | KSA | Cadaver | Hypertension | 314,023 |
| Female | 52 | O+ | 7.5 | KSA | Live | Chronic pyelonephritis | 447,232 |
| Male | 39 | O+ | 1.6 | The Philippines | Live | Diabetic nephropathy | 1,223,049 |
HCV – Hepatitis C virus; SLE – Systemic lupus erythematosus; KSA – Kingdom of Saudi Arabia
Frequency of single-nucleotide polymorphism genotypes with hepatitis C virus infection
| Genotypes | HCV RNA | Total, | OR (95% CI) | |
|---|---|---|---|---|
| Negative, | Positive, | |||
| rs12979860 (IL-28B) | ||||
| CC | 58 (89.2) | 7 (10.8) | 65 (43.6) | 0.89 (0.29–2.75) |
| CT | 59 (86.8) | 9 (13.2) | 68 (45.6) | 1.39 (0.46–4.27) |
| TT | 15 (93.8) | 1 (16.2) | 16 (10.8) | 0.49 (0.02–3.96) |
| rs2228145 (IL-6 receptor) | ||||
| AA | 67 (90.5) | 7 (9.5) | 74 (49.7) | 0.68 (0.22–2.09) |
| AC | 46 (86.8) | 7 (13.2) | 53 (35.6) | 1.31 (0.42–4.06) |
| CC | 19 (86.4) | 3 (13.6) | 22 (14.7) | 1.27 (0.26–5.41) |
| rs1800795 (IL-6 promoter) | ||||
| GG | 97 (88.2) | 13 (11.8) | 110 (73.8) | 1.17 (0.33–4.59) |
| GC | 32 (88.9) | 4 (11.1) | 36 (24.2) | 0.96 (0.24–3.49) |
| CC | 3 (100) | 0 | 3 (2.0) | 0.00 (0.0–15.87) |
HCV – Hepatitis C virus; IL – Interleukin; OR – Odds ratio; CI – Confidence interval
Association of genotype groups with hepatitis C virus infection
| IL-28B/IL-6R/IL-6P | HCV RNA | Total, | OR (95% CI) | |
|---|---|---|---|---|
| Negative, | Positive, | |||
| CC/AA/GG | 21 (84) | 4 (16) | 25 (16.8) | 0.6 (0.18–2.38) |
| CC/AA/GC | 5 (83.3) | 1 (16.7) | 6 (4) | 0.6 (0.08–15.8) |
| CC/AC/GG | 16 (94.1) | 1 (5.9) | 17 (11.4) | 2.2 (0.35–49.5) |
| CC/AC/GC | 7 (100) | 0 | 7 (4.7) | Undefined |
| CC/CC/GG | 8 (88.9) | 1 (1.1) | 9 (6) | 1.0 (0.15–24.5) |
| CC/CC/GC | 1 (100) | 0 | 1 (0.7) | Undefined |
| CT/AA/GG | 24 (96) | 1 (4) | 25 (16.8) | 3.5 (0.59–78.3) |
| CT/AA/GC | 7 (87.5) | 1 (12.5) | 8 (5.4) | 0.9 (0.13–21.6) |
| CT/AC/GG | 12 (66.7) | 6 (33.3) | 18 (12.1) | 5.4 (1.58–17.3) |
| CT/AC/GC | 4 (100) | 0 | 4 (2.7) | Undefined |
| CT/AC/CC | 2 (100) | 0 | 2 (1.3) | Undefined |
| CT/CC/GG | 4 (100) | 0 | 4 (2.7) | Undefined |
| CT/CC/GC | 6 (85.7) | 1 (14.3) | 7 (4.7) | 0.8 (0.10–18.7) |
| TT/AA/GG | 9 (100) | 0 | 9 (6) | Undefined |
| TT/AA/CC | 1 (100) | 0 | 1 (0.7) | Undefined |
| TT/AC/GG | 2 (100) | 0 | 2 (1.3) | Undefined |
| TT/AC/GC | 2 (100) | 0 | 2 (1.3) | Undefined |
| TT/CC/GG | 1 (100) | 0 | 1 (0.7) | Undefined |
| TT/CC/GC | 0 | 1 (100) | 1 (0.7) | Undefined |
| Total | 132 (88.6) | 17 (11.4) | 149 | |
Twenty-seven possible genotypes could be generated of the combination of the two alleles at each of the three loci; however, only 19 genotypes were present in our study population. HCV – Hepatitis C virus; IL – Interleukin; OR – Odds ratio; CI – Confidence interval
Correlation between genotypes and hepatitis C virus viral load
| Genotypes | HCV viral load | Total, | OR (95% CI)* | |
|---|---|---|---|---|
| <105 IU/ml, | >105 IU/ml, | |||
| rs12979860 (IL-28B) | ||||
| CC | 5 (71.4) | 2 (28.6) | 7 (41.2) | 1.74 (0.14–21.3) |
| CT | 7 (77.8) | 2 (22.2) | 9 (52.9) | 0.86 (0.07–10.5) |
| TT | 1 (100) | 0 | 1 (5.9) | 0 (0.0–61.75) |
| rs2228145 (IL-6 receptor) | ||||
| AA | 4 (57.1) | 3 (42.9) | 7 (41.2) | 5.96 (0.48–195.4) |
| AC | 7 (100) | 0 | 7 (41.2) | 0 (0.0–1.38) |
| CC | 2 (66.7) | 1 (33.3) | 3 (17.6) | 1.76 (0.05–31.1) |
| rs1800795 (IL-6 promoter) | ||||
| GG | 10 (76.9) | 3 (32.1) | 13 (76.5) | 0.9 (0.064–31.2) |
| GC | 3 (75.0) | 1 (25.0) | 4 (23.5) | 1.1 (0.03–15.5) |
| CC | 0 | 0 | 0 | – |
*Mid-P exact test. HCV – Hepatitis C virus; IL – Interleukin; OR – Odds ratio; CI – Confidence interval